If you click “Continue” below, you will leave the current site and be taken to a site maintained by a third party that is solely responsible for its content. Amgen provides this link as a service to website visitors. Amgen is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click here to view the American College of Cardiology/American Heart Association Task Force guidelines for the management of blood cholesterol.
Click here to view the 2019 European Society of Cardiology and European Atherosclerosis Society Task Force guidelines for the management of dyslipidemias.
Click here to view the American Association of Clinical Endocrinologists and American College of Endocrinology consensus statement for the management of dyslipidemia and prevention of cardiovascular disease.
Click here to view the American College of Cardiology’s ECDP guidance on the role of nonstatin therapies for LDL-C lowering in the management of ASCVD risk.
These third-party resources are for your information only. Amgen does not endorse and is not responsible for the content included in these resources.
Watch experts discuss current cholesterol guidelines, discharge protocol, and routine follow-up in patients with recent myocardial infarction (MI).
Watch experts discuss the healthcare professional (HCP)/patient conversation regarding the importance of LDL-C lowering for patients with recent MI.
Do your patients know their ASCVD journey by heart? Consider sharing this resource to inform your patients of what they can expect after an ASCVD event.
Download PDF
View this patient-friendly interactive artery showing the plaque buildup over time.
Take Me ThereDownload this overview that explains the scientific progression of atherosclerosis and ASCVD, and includes clinical guidelines and recommendations for the treatment of patients with very high-risk ASCVD.
Learn more about atherosclerosis and opportunities to optimize management of ASCVD.